Summary
- The government intends to amend the Human Medicines Regulations 2012 to clarify which emerging therapies fall within the gene therapy medicinal product category.
- The proposals explicitly address synthetic or recombinant nucleic acids and sequence-specific genome editing.
- International notification and parliamentary approval remain necessary, while existing medicine safety, quality and efficacy standards will continue to apply.
The UK government is preparing to update the legal definition of gene therapy medicinal products, giving developers of synthetic genetic medicines and newer genome-editing treatments a clearer regulatory framework. The Medicines and Healthcare products Regulatory Agency confirmed on 19 November that the changes will progress towards legislation following a consultation in which 83% of respondents supported the proposals.
The amendments would change the Human Medicines Regulations 2012 to accommodate technologies developed since the original advanced therapies definitions were established. The government wants the classification of gene therapy medicinal products to reflect how emerging treatments operate rather than rely on descriptions associated with earlier forms of genetic medicine.
The proposals were developed through a joint consultation conducted by the MHRA and the Department of Health in Northern Ireland, drawing responses from biotechnology companies, researchers, NHS organisations, patient groups and professional bodies. The changes remain subject to international notification procedures and parliamentary approval before becoming law.
The agency has emphasised that the new definition will not reduce the safety, quality or efficacy requirements applied to medicines. Existing licensed products will not need to undergo reclassification solely because the legal terminology changes.
Older definitions do not cover every new technique
Gene therapies use genetic material or processes involving genetic instructions to treat disease. Advances in biotechnology have expanded the methods available to researchers, including synthetic nucleic acids and techniques capable of making changes at specific locations within a genome.
Earlier regulatory definitions were developed when the range of available technologies was narrower. As new approaches emerged, developers could encounter uncertainty about whether their products belonged within the established gene therapy medicinal product category.
That classification affects the framework under which a medicine is developed and assessed. It can influence the documentation, regulatory advice and technical evidence manufacturers need to prepare as they move through research, clinical investigation and potential authorisation.
Uncertainty can be commercially significant because advanced medicines require substantial investment over long development periods. A biotechnology company may need to make decisions about manufacturing methods, clinical programmes and external partnerships before its product is sufficiently advanced to seek approval.
Establishing the applicable regulatory category earlier can help the organisation understand which requirements will govern its development programme. It does not guarantee a shorter or less expensive approval process, but it can reduce ambiguity around the route the product is expected to follow.
The MHRA’s proposed changes aim to make the definition more technologically neutral, allowing the legislation to accommodate therapies that did not exist when the earlier framework was established.
The proposed definition focuses on mechanism
Under the planned amendment, a gene therapy medicinal product would be classified by reference to whether its active substance contains recombinant or synthetic nucleic acid that undergoes transcription or translation, or whether its mechanism of action involves sequence-specific genome editing.
Transcription and translation are biological processes through which genetic information is used to produce functional molecules, including proteins. Incorporating these concepts into the definition allows the framework to consider the biological activity involved rather than simply the origin of the genetic material.
Sequence-specific genome editing addresses another category of treatment. Such techniques are designed to alter genetic information at particular locations, potentially enabling approaches that differ from more conventional methods of introducing genetic material into cells.
The revised wording is intended to clarify how these newer technologies fit within established medicines regulation. Nevertheless, classification will still depend on the characteristics and mechanism of the individual product rather than a blanket assumption that every treatment containing synthetic genetic material is a gene therapy.
Manufacturers will need to examine the final legislative wording carefully. Small differences in the mechanism of action can be relevant to classification, particularly where products combine genetic materials with other therapeutic technologies.
Regulatory certainty does not remove clinical risk
Modernising the definition may help developers determine the applicable regulatory pathway, but gene therapies will continue to require evidence addressing safety, quality and efficacy before receiving marketing authorisation.
Advanced treatments can present complex manufacturing requirements because their biological characteristics must remain sufficiently consistent between batches. Developers may need specialist analytical methods to establish product identity, purity and performance.
Clinical evaluation can be demanding where the effects of a genetic intervention may persist over time. Depending on the treatment, regulators may require evidence of durability, potential adverse consequences and the suitability of monitoring arrangements.
Changing the terminology used to classify a medicine cannot substitute for that work. A clearer category helps establish the rules under which evidence is assessed, but the evidence itself must still support the use of the individual treatment.
The agency has also indicated that medicines already authorised will not need to be reclassified. That provision is intended to preserve regulatory continuity for existing products while the framework is updated to accommodate future technologies.
For companies developing novel therapies, the commercial advantage is therefore more closely connected to regulatory predictability than the relaxation of approval standards.
International development adds another constraint
Biotechnology research and pharmaceutical manufacturing frequently operate across several countries. A medicine may be developed through international research partnerships, evaluated in multinational clinical trials and manufactured using materials or services supplied from different jurisdictions.
Regulatory definitions can affect those activities when developers seek authorisation in multiple markets. If similar technologies are classified differently, companies may need to prepare additional documentation or adapt their development strategy to meet separate requirements.
The government’s proposed approach reflects an intention to improve alignment with advances in the field, although updating UK legislation does not establish identical requirements in other countries.
International notification is among the procedures still required before the amendment can take effect, while the final legislative wording must also receive parliamentary approval.
The proposal forms part of a broader effort to support Britain’s life sciences sector, where companies depend on access to research infrastructure, specialist talent, investment and a regulatory system capable of assessing new technologies.
Clearer classifications may support those conditions by giving developers a more predictable account of how emerging treatments will be regulated, but the commercial outcome will continue to depend on clinical progress, manufacturing capability and whether individual therapies demonstrate meaningful benefits.
The MHRA will now progress the necessary legislative work. Until the changes take legal effect, manufacturers must continue applying the existing framework, while the final amendment will determine how synthetic gene therapies and sequence-specific genome-editing treatments are classified in future.












